PRIMO 2017 – Day One Recap and Highlights

The sun peaked out of the clouds as the final discussion concluded day one of the 2nd Annual Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Meeting – a day filled with engaging dialogue between faculty and attendees.

Day one saw lively discourse covering the topics of melanoma, head and neck cancer, lung cancer, and gastrointestinal malignancies, led by meeting Co-chairs Dr. Julie Brahmer, Dr. Julie Vose, and an internationally-renowned faculty. Dr. Sanjiv Agarwala of Temple University in Philadelphia, PA, kicked off day one’s session with back-to-back presentations, which set an energetic tone for the day. From there, attendees heard a variety of talks covering material related to the effectiveness of biomarker testing in lung cancer, targeted and immunotherapeutic options in advanced head and neck cancer, as well as the continuing evolution of immuno and targeted treatment options for lung cancer patients. These talks then culminated into a vivacious faculty panel, spurring conversation amongst faculty and attendees – a fitting way to end the morning session.

After a brief lunch period, attendees returned to the general session room for an afternoon dedicated to gastrointestinal malignancies. Dr. Alan Venook of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, CA, drove the session, presenting three talks, including an audience-engaging case study. This again led to a faculty panel ripe with discourse between the session faculty and audience, helping end the first day as it started – with buzz.

Day One Highlights:

From Dr. Agarwala’s presentation, “Current Approach to Melanoma”:

  • Immunotherapy with CPB is a front-line option for all patients, as anti-PD1 beats anti-CTLA4, both of which beat chemotherapy, and combinations look better than single CPB.

From Dr. Suresh Ramalingam, Winship Cancer Center, Emory University, talk “Today’s Targeted Treatment of NSCLC: The Continuing Revolution”:

  • Targeted therapy improves outcomes for patients with EGFR, ALK, and ROS1, aiding molecular testing as an integral part of diagnostic work up of NSCLC.

From Dr. Venook’s presentation, “Individualizing Treatment for Patients With Metastatic Colorectal Cancer”

  • There is need to categorize subsets of colorectal cancer, as well as a need to understand and overcome RAS.

Leave a Reply

Your email address will not be published. Required fields are marked *